Company / Cost of Revenue
IGC Pharma, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$652.0K
FY2025
5-year range
$203.0K / $4.0M
FY2021-FY2025
Trend
+39.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 10 years, ranging from $203,000 in FY2023 to $7M in FY2016.
Based on SEC 10-K filings.
$652,000 in FY2025 with a 5-year CAGR of -33.4%.
Increased from $203,000 to $652,000 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -6.0%
- 5-Year CAGR
- -33.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -33.4%, indicating a declining trend.
- In FY2025, cost of revenue increased 39.0% year-over-year.
- Peak cost of revenue was recorded in FY2016.
- Lowest cost of revenue in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $652.0K | +39.0% |
| FY2024 | $469.0K | +131.0% |
| FY2023 | $203.0K | -74.1% |
| FY2022 | $785.0K | -80.2% |
| FY2021 | $4.0M | -20.6% |
| FY2020 | $5.0M | +136.1% |
| FY2019 | $2.1M | +482.9% |
| FY2018 | $362.1K | -93.4% |
| FY2017 | $5.5M | -22.2% |
| FY2016 | $7.1M | +275.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026